Tirzepatide Beats Semaglutide for Weight Loss in Head-to-Head Meta-Analysis

Systematic review and meta-analysis of studies directly comparing tirzepatide and semaglutide for weight management. Four databases (PubMed, EMBASE, Web of Science, Cochrane Library) were searched through April 2025. Seven studies met inclusion criteria: 5 observational studies and 2 randomized controlled trials, with follow-up ranging from 6 to 12 months. Data were pooled using random-effects models in Review Manager 5.4.1.

With tirzepatide and semaglutide both becoming blockbuster weight-loss drugs, patients and doctors need to know which works better. This is one of the first meta-analyses to pool head-to-head comparison data, providing stronger evidence than individual studies alone. The finding that tirzepatide's dual-receptor approach outperforms GLP-1-only targeting has implications for drug selection and future drug development.

The incretin-based obesity drug market is the fastest-growing pharmaceutical segment in history. While both semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) have shown remarkable efficacy individually, the relative advantage of dual GIP/GLP-1 receptor agonism over GLP-1 alone is a critical question for the field. This meta-analysis adds to growing evidence that dual-receptor targeting provides additional weight-loss benefit, which may drive development of more multi-receptor peptide drugs.

High heterogeneity (I² >90%) indicates substantial variation across studies, weakening the pooled estimates. Only 2 of 7 studies were randomized controlled trials; the remaining 5 were observational, introducing potential confounding. Follow-up was limited to 6–12 months. Different doses and formulations of both drugs were used across studies. Safety and tolerability were not comprehensively compared.